Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $633.00

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by Canaccord Genuity Group from $612.00 to $633.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on MDGL. Wells Fargo & Company started coverage on shares of Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 target price for the company. UBS Group reiterated a “buy” rating and issued a $735.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price for the company in a research report on Tuesday, August 4th. Citigroup upped their target price on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Truist Financial reaffirmed a “buy” rating and issued a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $706.87.

Madrigal Pharmaceuticals Trading Down 0.1%

Shares of NASDAQ:MDGL traded down $0.47 on Wednesday, hitting $399.63. The company had a trading volume of 1,087,445 shares, compared to its average volume of 313,609. Madrigal Pharmaceuticals has a 1 year low of $353.54 and a 1 year high of $615.00. The firm has a market capitalization of $9.23 billion, a price-to-earnings ratio of -66.83 and a beta of -0.98. The firm’s 50-day simple moving average is $486.74 and its two-hundred day simple moving average is $497.41. The company has a quick ratio of 2.94, a current ratio of 3.20 and a debt-to-equity ratio of 0.65.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The business had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. During the same period last year, the business posted ($5.08) earnings per share. Equities analysts anticipate that Madrigal Pharmaceuticals will post -3.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 6,362 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the completion of the sale, the chief executive officer directly owned 202,967 shares in the company, valued at $108,707,095.53. The trade was a 3.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon Kelley sold 1,077 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $400.00, for a total transaction of $430,800.00. Following the sale, the general counsel directly owned 10,397 shares of the company’s stock, valued at $4,158,800. The trade was a 9.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,324 shares of company stock valued at $7,011,982. Insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MDGL. William Blair Investment Management LLC increased its holdings in Madrigal Pharmaceuticals by 4.0% during the third quarter. William Blair Investment Management LLC now owns 337,035 shares of the biopharmaceutical company’s stock valued at $169,852,000 after buying an additional 12,912 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Madrigal Pharmaceuticals by 2.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 50,545 shares of the biopharmaceutical company’s stock valued at $25,473,000 after acquiring an additional 1,251 shares during the period. Fifth Third Bancorp grew its position in shares of Madrigal Pharmaceuticals by 3.5% during the 3rd quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 28 shares during the period. Maryland State Retirement & Pension System increased its stake in shares of Madrigal Pharmaceuticals by 17.3% in the 3rd quarter. Maryland State Retirement & Pension System now owns 1,098 shares of the biopharmaceutical company’s stock worth $553,000 after purchasing an additional 162 shares in the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter worth $200,000. 98.50% of the stock is currently owned by institutional investors.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.